Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE.

ABSTRACT: We report the impact of ¹⁷⁷Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (¹⁷⁷Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures. Results: Patients (intent-to-treat) who received ¹⁷⁷Lu-DOTATATE experienced a significantly greater decl

SUBMITTER: Strosberg JR 

PROVIDER: S-EPMC8612179 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature